Clinical-stage regenerative medicine firm CollPlant has received CE mark approval for its flowable gel, Vergenix FG, to treat chronic and acute wounds.
The new wound filler uses the firm’s tobacco plant-based technology, which will help in the large scale production of recombinant human collagen (rhCollagen).
Vergenix FG needs only a single (one-time) treatment compared against standard of care that requires multiple and repetitive treatments.
According to the company, the clinical trial results demonstrated that Vergenix FG is safe and effective for use on human subject and showed better wound closure rates.
CollPlant CEO Yehiel Tal said: "Vergenix FG is one of the world’s first medical devices containing a recombinant collagen sourced from plants.
"We are now seeking distributors in Europe in order to set up the necessary sales infrastructure, where initial sales are expected to begin in 2016."
CollPlant develops and markets tissue repair products for the orthobiologics and advanced wound care markets.
The firm’s other products include Vergenix soft tissue repair matrix, for the treatment of tendinopathy, as well as Vergenix bone void filler for use in spinal fusion procedures and trauma.